Collective reviewFibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications
Abbreviations and Acronyms
DIC
disseminated intravascular coagulation
INR
international normalized ratio
LY30
lysis at 30 minutes
MCF
maximum clot firmness
ML
maximum lysis
PAI-1
plasminogen activator inhibitor 1
ROTEM
rotational thromboelastometry
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
TAFI
thrombin activatable fibrinolysis inhibitor
TEG
thrombelastography
tPA
tissue plasminogen activator
VTE
venous thromboembolism
Cited by (0)
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Drs HB Moore and EE Moore have received grant support from Haemonetics and Instrumentation Laboratories; have patents pending related to coagulation and fibrinolysis diagnostics and therapeutic fibrinolytics; and are co-founders with stock options in Thrombo Therapeutics, Inc. Dr EE Moore has received grant support from Stago, Hemosonics, and Diapharma. Dr Meizoso has nothing to declare.
© 2021 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.